Atropos Health Adds Ontada Oncology Data to Expand Community Cancer Coverage in Real-World Evidence Network
Atropos Health has integrated data from Ontada, a McKesson company focused on community oncology, into the Atropos Evidence Network. The collaboration adds Ontada’s proprietary iKnowMed oncology dataset, sourced in part from The US Oncology Network, which treats more than 1.4 million cancer patients each year across more than 80 tumor types.
The Atropos Evidence Network now includes broader coverage of community oncology settings, where an estimated 85 percent of cancer patients receive care. Researchers and clinical users running queries through Atropos’ GENEVA OS platform can now access this data, which is evaluated for relevance using the company’s "Real-World Fitness Score". The system enables localized, privacy-preserving queries across distributed real-world data sources without centralizing sensitive information.
The announcement follows the introduction of Atropos Health’s Federated Nodal Deidentification Technology in March, which supports longitudinal analysis within the GENEVA OS platform while preserving patient privacy across data nodes. The expanded oncology network is designed to support treatment decision-making, protocol design, and life sciences research in community oncology.
See also: Merck Partners with Atropos Health to Accelerate Real-World Evidence Generation
Earlier this year, Atropos Health also entered a collaboration with Merck to accelerate real-world evidence generation using its suite of tools, including GENEVA OS, the Green Button, and the Atropos Evidence Network. The partnership focuses on rapid cohort generation and near real-time analytics, with the aim of producing publication-grade evidence in as little as 48 hours. Merck’s data science teams are working with Atropos to replicate studies, fill evidence gaps, and validate insights using data evaluated through the Real-World Fitness Score.
Topics: HealthTech
